<DOC>
	<DOCNO>NCT00663195</DOCNO>
	<brief_summary>The purpose study evaluate effect spironolactone circulate MMP level insulin resistance patient chronic heart failure .</brief_summary>
	<brief_title>Effects Spironolactone Matrix Metalloproteinases ( MMPs ) Heart Failure</brief_title>
	<detailed_description>Myocardial fibrosis observe failing heart . MMPs consider marker fibrosis . Recently , circulate MMPs measure elevated patient chronic heart failure ( CHF ) . It report spironolactone improves myocardial fibrosis CHF animal model . Therefore , purpose study evaluate effect spironolactone circulate MMP level patient chronic heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<criteria>chronic stable heart failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>heart failure</keyword>
	<keyword>fibrosis</keyword>
	<keyword>MMP</keyword>
	<keyword>spironolactone</keyword>
	<keyword>furosemide</keyword>
</DOC>